SYDNEY, Aug 18 (Reuters) - Australia’s CSL Ltd (CSL.AX), the world’s second biggest blood products maker, is looking at small acquisitions but is not considering large or transformational deals at this stage, its chief executive said.
The company earlier said it will buy back A$900 million ($818 million) of its shares.
The key challenge for CSL is to find a new source of growth after its planned $3.1 billion takeover of U.S. rival Talecris Biotherapeutics TLCR.O was blocked by U.S. regulators in 2009. Spain’s Grifols (GRLS.MC) is now trying to buy Talecris for $3.4 billion. ($1=A$1.10) (Reporting by Morag Mackinnon; editing by Balazs Koranyi)